Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden–High Ovarian Cancer

Overview of attention for article published in JCO Precision Oncology, January 2026

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 5 news outlets

Readers on

mendeley: 3 Mendeley

So far, Altmetric has seen 5 news stories from 5 outlets.

Jan 28, 2026 | News ROSELLA Trial Meets OS End Point and More Ovarian Cancer News

Oncology Nursing News, 28 Jan 2026

Recent clinical developments in the treatment of platinum-resistant ovarian cancer (PROC) have introduced several novel…

Gemogenovatucel-T Exhibits Survival Benefit in Epithelial Ovarian Cancer

Cancer Network, 15 Jan 2026

Maintenance therapy with gemogenovatucel-T (Vigil), an autologous tumor-cell immunotherapy, exhibited a significant survival…

Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology

BioSpace, 15 Jan 2026

Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with…

Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology

Pharmaceutical Daily, 15 Jan 2026

Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.